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Abstract
Objectives—To characterize psychotropic medication use before and after traumatic brain injury
(TBI) hospitalization among older adults. A secondary objective is to determine how receipt of
indicated pharmacologic treatment for anxiety and post-traumatic stress disorder (PTSD) differs
following TBI.
Design—Retrospective cohort
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Setting—United States
Participants—Medicare beneficiaries age ≥65 hospitalized with TBI 2006-2010 with continuous
drug coverage for 12 months before and after TBI (n=60,276).
Measurements—We obtained monthly psychotropic medication use by drug class and specific
drugs from Medicare Part D drug event files. International Classification of Disease, 9th Edition
CM, codes were used to define anxiety (300.0x) and PTSD (309.81).
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Results—Average monthly prevalence of psychotropic medication use among all patients
hospitalized for TBI was 44.8%; antidepressants comprised 73%. Prevalence of psychotropic
medication use increased from 2006-2010. Following TBI, psychotropic medication use increased
slightly (odds ratio (OR) 1.05; 95% confidence interval (CI) 1.03, 1.06.) Tricyclic antidepressant
use decreased post-TBI (OR 0.76; 95% CI 0.73, 0.79) while use of the sedating antidepressants
mirtazapine (OR 1.31; 95% CI 1.25, 1.37) and trazadone (OR 1.11; 95% CI 1.06, 1.17) increased.
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Antipsychotic (OR 1.15; 95% CI 1.12, 1.19) use also increased post-TBI. Beneficiaries newly
diagnosed with anxiety (OR 0.42; 95% CI 0.36, 0.48) and/or PTSD (OR 0.39; 95% CI 0.18, 0.84)
post-TBI were less likely to receive indicated pharmacologic treatment.
Conclusions—Older adults hospitalized with TBI have a high prevalence of psychotropic
medication use yet are less likely to receive indicated pharmacological treatment for newly
diagnosed anxiety and PTSD following TBI.
Keywords
Traumatic Brain Injury; Psychotropic Medications; Older Adults; Neuropsychiatric disorders

Introduction
Author Manuscript

Traumatic brain injury (TBI) causes significant morbidity among older adults, resulting in
over 142,000 emergency department visits and 81,500 hospitalizations annually in the
United States.1 Further, rates of TBI among older adults are increasing.1,2 Older adults have
the highest rates of hospitalization and mortality following TBI and are more likely to
experience poor cognitive and functional outcomes, nursing home placement, and mortality
compared to younger adults with similar injury severity.1,3-6

Author Manuscript

Individuals with TBI are at increased risk of neuropsychiatric disorders due to 1) trauma to
brain regions involved in emotional regulation and behavioral control, and 2) longer-term
cognitive and physical disability from the TBI resulting in loss of employment, previously
enjoyed activities, family support, and social contacts.7-10 Although there is good evidence
of the increased risk of neuropsychiatric disorders following TBI, there is insufficient highlevel evidence supporting the use of any pharmacologic treatments for neuropsychiatric
disorders following TBI.10,11 Brain injury increases the risk of adverse events such as
seizures and stroke, raising concerns that treatments for neuropsychiatric disorders may not
have the same safety or efficacy in individuals with TBI.11-15 Physicians currently rely on
evidence from a few small clinical trials and treatment of neuropsychiatric disturbances in
the general population to guide treatment decisions for individuals with TBI. 8,11,12,16-20
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Preliminary to the conduct of comparative safety analyses, a thorough examination of
current use of psychotropic medications among individuals with TBI is warranted. Hence,
the objective of this study is to characterize psychotropic medication use before and after
TBI among older adults, a vulnerable population for whom there is little data on treatment of
TBI neuropsychiatric disorders. As a secondary objective, we examine whether receipt of
indicated pharmacologic treatment for anxiety and post-traumatic stress disorder (PTSD) is
impacted by TBI.

Methods
We conducted a retrospective analysis of Medicare administrative claims data obtained from
the Centers for Medicare & Medicaid Services (CMS) Chronic Condition Data Warehouse
(CCW). In the United States, Medicare provides health insurance to individuals aged 65 and
older and younger individuals with disabling conditions. Medicare consists of three Parts: A
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(hospital), B (medical), and D (outpatient prescription medications). Beneficiaries can also
enroll in Part C, in which a commercial insurer provides benefits. All elderly Medicare
beneficiaries hospitalized with TBI during 2006-2010 were eligible. Inclusion criteria were
age ≥65 at TBI, first TBI, and survival to hospital discharge. We defined TBI by searching
for International Classification of Disease, 9th Revision Clinical Modification (ICD-9-CM)
codes 800.xx, 801.xx, 803.xx, 804.xx, 850.xx- 854.1x, 950.1-950.3, 959.01) in any position
on an inpatient claim. These ICD-9-CM codes represent the Centers for Disease Control and
Prevention's (CDC) case definition for TBI, which previously has been reported to have a
sensitivity of 89% to detect severe TBI and a positive predictive value of 93% to correctly
identify TBI-related hospitalizations.21,22

Psychotropic Medications
Author Manuscript
Author Manuscript

We searched Medicare Part D prescription drug event files for evidence of psychotropic
medication use. We created 30-day periods pre- and post-TBI hospitalization and defined
medication use as 1) a filled prescription for any psychotropic medication; or 2) a proportion
of days covered (number of daily doses in the prescription/number of days in the month) for
any psychotropic medication >0. We defined five classes of psychotropic medications as:
antidepressants, antipsychotics, mood stabilizers and anti-seizure medications, other
anxiolytics (e.g. buspirone, hydrozyzine), and miscellaneous psychotropics (e.g. zolpidem,
zaleplon). Appendix 1 contains a complete list of drug names, classes to which they were
assigned, and indicated use in treatment of anxiety of PTSD. To ensure adequate time to
capture patterns of medication use as well as comorbidities and diagnosis of
neuropsychiatric disturbances, we required twelve months continuous Medicare Parts A, B,
and D with no Part C (Medicare Advantage (HMO)) coverage both pre- and post-TBI
hospitalization (twenty-four months total follow-up). Medications used during the
hospitalization episode and during a skilled nursing facility (SNF) stay of <100 days are not
consistently present in the Part D drug event file.

Anxiety and PTSD
Anxiety disorder (henceforth called anxiety) was defined as the presence of ICD-9-CM
codes 300.0x on any inpatient or outpatient claim during the study period and PTSD as
ICD-9-CM code 309.81. The first date of diagnosis occurring pre- and post-TBI was
recorded and used to identify individuals with pre- or post-TBI disorders. We also created a
variable indicating a new diagnosis post-TBI for those who did not have a previous anxiety
or PTSD diagnosis.

Author Manuscript

Covariates
Demographic and enrollment characteristics were obtained from the CCW enrollment file
and baseline comorbidities at TBI hospitalization were determined using CMS's CCW
flagged comorbid conditions.23 These 27 chronic conditions are identified based on the
presence of ICD-9 codes on inpatient, skilled nursing, home health, or outpatient claims
using algorithms defined by CMS. The date of first diagnosis is listed for each flagged
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condition. We used these to create time-varying comorbidity diagnoses throughout the study
period.
Diagnosis and treatment of depressive disorder (depression) could strongly influence receipt
of treatment for anxiety or PTSD, especially since medications used to treat these conditions
often overlap. Therefore, we created indicator variables for pre- and post-TBI depression
diagnoses, defined as the presence of ICD-9-CM codes 296.2, 296.3, 300.4, and 311 on any
inpatient or outpatient claim during the study period. We also created a variable indicating
new diagnosis of depression post-TBI for those without a depression diagnosis pre-TBI.

Data Analysis
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Distributions of demographic and clinical variables in the study population were assessed
overall and stratified by receipt of at least one psychotropic medication at any time during
the study period. Average monthly prevalence of psychotropic use was calculated by
category for the twelve months prior to and following TBI hospitalization. Antidepressants
comprise the majority of psychotropic use; therefore we also calculated the average monthly
prevalence of use of the most common antidepressants: selective serotonin re-uptake
inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), and tri-cyclic
antidepressants (TCAs). The ‘other’ antidepressants included mirtazapine, bupropion,
trazadone, and monoamine oxidase inhibitors. We also calculated average prevalence of use
for the twenty most prevalent individual psychotropic medications during the pre- and postTBI periods. Finally, we created an indicator variable for use of more than one psychotropic
medication class at one time.
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To test time trends in monthly prevalence of psychotropic use over the study period, we used
linear regression, evaluating trends prior to and following the TBI hospitalization separately.
We also evaluated trends over the entire study period, excluding the first two months
following injury because of incomplete reporting of medication use during hospitalization
and subsequent skilled nursing facility stay. These models were adjusted only for time, and
informed adjustment of generalized estimating equation models. To test whether TBI
hospitalization impacted psychotropic use, we used generalized estimating equations with a
logistic model, accounting for repeated observations and time. As before, we excluded the
first two months following injury.

Author Manuscript

We examined whether individuals newly diagnosed with anxiety or PTSD following TBI
used the same amount of psychotropic medication compared to individuals without TBI.
However, Medicare beneficiaries hospitalized with TBI differ from other Medicare
beneficiaries in that they are older with a greater burden of comorbid illness, complicating
efforts to identify a suitable comparison group.24 Our prior study examining post-TBI
treatment of depression addressed this issue by using the pre-TBI period as the control.25 We
used similar methodology to compare receipt of treatment for anxiety and PTSD during the
pre- and post-TBI periods.
To focus on new use of psychotropic medications associated with diagnosis of anxiety or
PTSD, we excluded beneficiaries with any use of medications used to treat anxiety or PTSD
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(depending on the model) during the six months prior to diagnosis. To accurately report use
of psychotropic medications associated with diagnosis of anxiety or PTSD at the monthly
level, we created time-varying indicators for new diagnoses using dates of first ICD-9 CM
code for anxiety disorder or PTSD during the pre- and post-TBI period. For this analysis, we
compared receipt of treatment pre- vs post-TBI among beneficiaries with new anxiety or
PTSD diagnoses. The pre- and post-TBI groups were mutually exclusive, but an individual
with both anxiety and PTSD could contribute follow-up time to both cohorts. We used
generalized estimated equations with a logistic model to estimate the odds of psychotropic
medication receipt pre- vs post-TBI among beneficiaries newly diagnosed with anxiety or
PTSD. Covariates were selected for our models based on bivariate analysis (chi-square or
Student's t-test p-value < 0.001), a chi-square p-value <0.05 from type-III analysis, and a
10% or greater change in the effect measure parameter estimate.
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This study was approved by the Institutional Review Board of the University of Maryland,
Baltimore. All analysis was performed with SAS version 9.4 (SAS Institute, Cary, NC).

Results

Author Manuscript

There were 60,276 beneficiaries meeting inclusion criteria with twelve months continuous
Medicare Parts A, B, and D with no Part C coverage before and after TBI hospitalization. Of
these, 42,608 (71%) used a psychotropic medication at least once during the twenty-four
month study period (Table 1). Beneficiaries who used any psychotropic medication were
younger (80.4 (standard deviation (sd) 8.3) years vs. 81.1 (sd 8.3) years, Student's t-test,
Satterthwaite method df=32,614 p<0.001) and more likely to be female (71% vs. 60%,
Pearson's Χ2=582.2, p<0.001). They were more likely to have Alzheimer's disease and
related dementias (24% vs. 19%, Pearson's Χ2=2,548.7, p<0.001) and to have originally
qualified for Medicare benefits due to disability rather than age (14% vs. 8%, Pearson's
Χ2=423.6, p<0.001). Among beneficiaries who used psychotropic medications, 27% were
diagnosed with depression pre-TBI and 34% post-TBI, with 18% receiving first-time
diagnoses post-TBI. Anxiety was diagnosed among 14% pre-TBI and 17% post-TBI, and
10% received a first-time diagnosis post-TBI. PTSD was rarely diagnosed both pre- and
post-TBI (<1%).
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Average monthly prevalence of psychotropic medication use during the study period was
44.8% (Table 2). Prevalence of use of two or more psychotropic medications at the same
time was 14%. Antidepressants were the most commonly used class of medications, with
average monthly prevalence of 32.5% and of these, SSRIs were the most common (22.2%
average monthly prevalence). There was a significant time trend in use of psychotropic
medications over the entire study period (Student's t-test df =21, p<0.001)(Figure 1), even
when month three was excluded to account for incomplete reporting of medication use
during hospitalization and subsequent skilled nursing facility stay. Increased use over the
study period was observed for all psychotropics except TCAs (significant decrease in use,
Student's t-test df =21, p<0.001) and miscellaneous psychotropics (Student's t-test df =21,
p=0.12).
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The SSRIs sertraline and escitalopram were the most commonly used psychotropic
medications before and after TBI (Figure 2). Quetiapine was the most commonly used
antipsychotic both pre- and post-TBI. Prevalence of use of the anti-seizure agent
levetiracetam was low pre-TBI but increased five-fold post-TBI.
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Accounting for repeated observations and time, odds of using any psychotropic medication
were increased post-TBI (odds ratio (OR) 1.05; 95% confidence interval (CI) 1.03, 1.06,
Wald Χ2=36.2, df=1, p<0.001) (Table 2). Overall, antidepressant use decreased slightly postTBI, with TCAs showing the largest decrease in use (OR 0.76; 95% CI 0.73, 0.79, Wald
Χ2=178.5, df=1, p<0.001), even though other antidepressant use increased (OR 1.15; 95%
CI 1.11, 1.18, Wald Χ2=73.0, df=1, p<0.001 ). The increase in other antidepressant use postTBI was driven by mirtazapine (OR 1.31; 95% CI 1.25, 1.37, Wald Χ2=123.3, df=1,
p<0.001) and trazadone (OR 1.11; 95% CI 1.06, 1.17, Wald Χ2=18.3, df=1, p<0.001)(data
not shown). Antipsychotic use increased post-TBI (OR 1.15; 95% CI 1.12, 1.19, Wald
Χ2=103.0, df=1, p<0.001), driven by 15%-20% increases in the atypical antipsychotics
aripiprazole, quetiapine, olanzapine, and risperidone (data not shown). Mood stabilizer/antiseizure use increased significantly post-TBI (OR 1.21; 95% CI 1.19, 1.24, Wald Χ2=250.8,
df=1, p<0.001). The increase was largest for the anti-seizure drug levetiracetam (OR 4.80;
95% CI 4.37, 5.28, Wald Χ2=1,066.5, df=1, p<0.001)(data not shown).

Author Manuscript

There were 3,402 beneficiaries diagnosed with anxiety pre-TBI with no use of indicated
psychotropic medications during the six months prior to diagnosis and 1,676 beneficiaries
diagnosed with anxiety for the first time post-TBI and with no use of indicated psychotropic
medications for at least six-months prior to anxiety diagnosis, for a total of 5,078
beneficiaries. Our adjusted model contained terms for TBI, age, sex, race, calendar year,
Alzheimer's disease and related dementias, pre-TBI diagnosis of depression and post-TBI
diagnosis of depression (these variables were time-varying). Beneficiaries newly diagnosed
with anxiety post-TBI were less likely to receive indicated pharmacologic treatment (OR
0.42; 95% CI 0.36, 0.48, Wald Χ2=145.5, df=1, p<0.001)(Table 3).
There were 51 beneficiaries diagnosed with PTSD pre-TBI with no use of indicated
psychotropic medications during the six months prior to diagnosis and 34 beneficiaries
diagnosed with PTSD for the first time post-TBI with no use of indicated psychotropic
medications for at least six months prior to PTSD diagnosis, for a total of 85 beneficiaries.
Our adjusted model contained terms for TBI and original reason for Medicare entitlement
(age, disability, end-stage renal disease). Beneficiaries newly diagnosed with PTSD postTBI were less likely to receive indicated pharmacologic treatment (OR 0.39; 95% CI 0.18,
0.84, Wald Χ2=5.8, df=1, p=0.02) (Table 3).
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Discussion
In this national study of Medicare beneficiaries hospitalized with TBI, almost three-quarters
used psychotropic medications at least once and monthly prevalence of use increased over
the 24 month study period. The majority of those using psychotropic medications did not
receive a diagnosis of depression, anxiety, or PTSD during the study period. After
accounting for repeated measures and time, hospitalization for TBI resulted in decreases in
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antidepressant use after discharge while use of mood stabilizers/anti-seizure medications and
antipsychotics increased. Compared to individuals diagnosed with anxiety or PTSD pre-TBI,
those diagnosed post-TBI were much less likely to receive indicated pharmacological
treatment.

Author Manuscript

Although information on prevalence of psychotropic use is limited, prevalence of
antidepressant use (33%) in our study was much higher than prior estimates. Kantor et al.
(2015) assessed antidepressant use among participants ≥18 years in the National Health and
Nutrition Examination Survey and reported that during 2007-2010, 12% of study
participants reported using an antidepressant in the past 30 days.26 Depression has been
identified as a potential risk factor for TBI, hence our sample may have been enriched for
individuals with greater antidepressant use.27,28 Consistent with this hypothesis, the sample
population was majority female and had a high prevalence of Alzheimer's, two factors
associated with depression.29-31 Additionally, there is some evidence of an association
between SSRIs and increased risk of falls and fractures, suggesting that we may be
observing a risk factor for TBI, although our study did not examine this question.32,33

Author Manuscript

The SSRIs sertraline and escitalopram were the most commonly prescribed psychotropic
medications both pre- and post-TBI, consistent with results of a previous study conducted
among older adults and with currently used treatments for depression following TBI. 8,11,34
Odds of TCA use, which can lower the seizure threshold and is associated with increased
risk of metabolic and anticholinergic side-effects, decreased 24% compared with the preTBI period.8,11 This large decrease suggests prescriber awareness of potential adverse events
associated with TCA use following TBI that may be leading to either discontinuation or
switching from TCAs to a different psychotropic medication. There was an overall small but
significant decrease in antidepressant use not completely attributable to TCAs that supports
discontinuation following TBI and may reflect caution on the part of providers to continue
prescribing antidepressants, perhaps due to a desire to decrease polypharmacy or possibly
knowledge that certain antidepressants are associated with increased fall risk. Use of the
sedating antidepressants trazadone and mirtazapine increased moderately (15% increase in
odds of use) post-TBI, likely resulting from treatment of sleep disturbances, common
following TBI. 8 Finally, odds of use of atypical antipsychotics, among which quetiapine is
most commonly used, increased by a moderate 15% post-TBI. Quetiapine, and to a lesser
extent risperidone, is often used for the treatment of insomnia, agitation, and aggression
following TBI. 8
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Individuals newly diagnosed with anxiety and PTSD post-TBI were much less likely to
receive indicated medications for treatment of these disorders compared to similar
individuals diagnosed with anxiety and PTSD before TBI. This finding is consistent with our
previous results on treatment of depression following TBI and provides evidence that among
older adults, there is a disparity in receipt of treatment for the three most common
neuropsychiatric disorders following TBI.25 Older adults are more likely to initially consult
with a primary care provider for psychological problems and receive a psychiatric diagnosis
from a non-specialty setting.32 However, these providers may not feel comfortable
prescribing psychotropic medications following TBI in the absence of evidence based
recommendations.11,12,35 The disparity may also result from the perception that a
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psychological reaction to trauma is expected and will resolve on its own without treatment.
Cognitive impairment, common following TBI, may also impede filling prescribed
medications or following up with providers for refills.36

Author Manuscript

Limitations of this study include lack of a comparison group of Medicare beneficiaries who
were not hospitalized with TBI. Although we used the pre-TBI period for comparison, it is
likely that psychotropic medication use in this population is different from and possibly
higher than that of other Medicare beneficiaries. Information on TBI severity is missing
from administrative claims; however, neuropsychiatric disturbances occur regardless of TBI
severity and current pharmacologic treatments do not account for severity of injury.8,11
Furthermore, this study includes only beneficiaries hospitalized with TBI. These individuals
may have been more severely injured or more susceptible to complications compared to
those who were treated and released in the emergency department. If these factors were also
associated with psychotropic medication use, bias could result. Future studies should focus
on different populations to help determine the extent of this potential bias. Additionaly,
while we assessed filled prescriptions, we don't have information on medications prescribed
but not filled or adherence to filled prescriptions. Therefore, observed differences in
psychotropic medication use pre-post TBI may be due to lack of prescribing or lack of
follow-up on the part of the patient. Finally, we don't know the indications for which
beneficiaries were receiving psychotropic medications.
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Nonetheless, this is the largest study of psychotropic medication use among individuals with
TBI and it provides critical information on current usage patterns before and after TBI
hospitalization. Comparative safety and effectiveness analyses could initially target the
medications we identified as most often used. Furthermore, this study highlights a disparity
in receipt of pharmacological treatment for newly diagnosed anxiety and PTSD following
TBI. Future studies should focus on elucidated underlying reasons for the observed disparity
and whether younger adults are equally affected. More research is also needed to determine
the efficacy of psychotropic medications following TBI, their specific side-effects and drugdrug interactions and the role of non-pharmacological strategies. Physicians should be
cognizant of these factors and be extremely cautious in prescribing psychotropics in elderly
individuals with TBI who are often being treated pharmacologically for other medical
conditions.
In conclusion, Medicare beneficiaries hospitalized with TBI have a high prevalence of
psychotropic medication use both before and after TBI yet are less likely to receive indicated
pharmacological treatment for newly diagnosed anxiety and PTSD following TBI.
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Figure 1.

Author Manuscript

Monthly Prevalence of Psychotropic Medication Use among Medicare Beneficiaries
Hospitalized with Traumatic Brain Injury 2006-2010 During Twelve Months Pre- and PostTBI, n= 60,276
TBI – traumatic brain injury; SSRI – selective serotonin reuptake inhibitor; SNRI –
serotonin norepinephrine reuptake inhibitor; TCA – tricyclic antidepressant; AP –
antipsychotic; MS/AS – mood stabilizer/anti-seizure; PT – any psychotropic; MPT –
miscellaneous psychotropic; *Dip post-TBI is caused by incomplete capture of drug claims
data during hospitalization and subsequent skilled nursing facility stay
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Figure 2.

Average Monthly Prevalence of the Twenty Most Commonly Used Psychotropic
Medications among Medicare Beneficiaries During the Twelve Months Pre- and PostHospitalization with Traumatic Brain Injury 2006-2010, n= 60,276

Author Manuscript
Author Manuscript
Am J Geriatr Psychiatry. Author manuscript; available in PMC 2018 April 01.

Albrecht et al.

Page 13

Table 1

Author Manuscript

Baseline Characteristics of Medicare Beneficiaries Hospitalized with Traumatic Brain Injury 2006-2010 by
Receipt of Psychotropic Medications at any Time During the Study Period, n= 60,276

Age, mean (standard deviation)
Female sex, n(%)

1
p-value

Total Sample N= 60,276

Psychotropic Use, N=
42,608

No Psychotropic Use, N=
17,668

81.0 (8.3)

80.4 (8.4)

81.1 (8.3)

<0.001

40,735 (68)

30,057 (71)

10,678 (60)

<0.001

2

<0.001

Race/Ethnicity
White

53,030 (86)

37,081 (87)

14,949 (85)

Black

3,489 (6)

2,346 (6)

1,143 (6)

Other

4,757 (8)

3,181 (7)

1,576 (9)

Alzheimer's disease

13,439 (22)

10,103 (24)

3,336 (19)

<0.001

Chronic kidney disease

10,465 (17)

7,615 (18)

2,850 (16)

<0.001

6,190 (10)

4,562 (11)

1,628 (9)

<0.001

4,813 (8)

3,518 (8)

1,295 (7)

<0.001

Heart failure

8,582 (14)

6,220 (15)

2,362 (13)

<0.001

Ischemic heart disease

6,135 (10)

4,143 (10)

1,992 (11)

<0.001

Neurologic disease

7,341 (12)

5,661 (13)

1,680 (10)

<0.001

Rheumatoid arthritis / osteoarthritis

6,792 (11)

4,529 (11)

2,263 (13)

<0.001

13,664 (23)

9,804 (23)

3,860 (22)

0.002

Depression pre-TBI

12,027 (20)

11,573 (27)

454 (3)

<0.001

Depression post-TBI

15,429 (26)

14,692 (34)

737 (4)

<0.001

New depression post-TBI

8,396 (14)

7,798 (18)

598 (3)

<0.001

Anxiety pre-TBI

6,902 (11)

6,294 (14)

608 (3)

<0.001

Anxiety post-TBI

8,113 (13)

7,341 (17)

772 (4)

<0.001

5,017 (8)

4,438 (10)

579 (3)

<0.001

4

95 (<1)

88 (<1)

7 (<1)

<0.001

4

136 (<1)

124 (<1)

12 (<1)

<0.001

102 (<1)

90 (<1)

12 (<1)

<0.001

Comorbid conditions, n(%)

Author Manuscript

3

COPD

Diabetes

Stroke / transient ischemic attack
Psychological disorders, n (%)

Author Manuscript

New Anxiety post-TBI
PTSD pre-TBI
PTSD post-TBI

4

New PTSD post-TBI

2,5

OREC

<0.001

, n(%)

Age
Disability

6

ESRD +/− disability

52,823 (88)

36,584 (86)

16,239 (92)

7,322 (12)

5,924 (14)

1,398 (8)

131 (<1)

100 (<1)

31 (<1)

Author Manuscript

1

P-value from Pearson's X2 (1 degree of freedom except where noted) = 22.1-8,702.3, Student's t-tests for age (Satterthwaite method df=32,614)

2

df = 2

3

Chronic obstructive pulmonary disease

4

Post-traumatic stress disorder
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5

Original reason for Medicare entitlement

6

End stage renal disease

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
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Table 2

Author Manuscript

Average Monthly Prevalence of Psychotropic Medication Use and Odds Ratios Comparing Use Post- to Pre1

TBI , Adjusted for Time, among Medicare Beneficiaries Hospitalized with TBI 2006-2010 During Twelve
Months Pre- and Post-TBI, n= 60,276
2

Pre-TBI

Post-TBI

Entire Period

Odds Ratio (95% Confidence Interval)

Any Psychotropic Medication

41.8%

47.8%

44.8%

1.05 (1.03, 1.06)

36.2, <0.001

Any Antidepressant

30.9%

34.1%

32.5%

0.96 (0.95, 0.98)

25.7, <0.001

3

21.0%

23.4%

22.2%

0.96 (0.94, 0.97)

25.5, <0.001

4

4.2%

4.6%

4.4%

0.89 (0.86, 0.92)

48.6, <0.001

5

3.8%

2.8%

3.3%

0.76 (0.73, 0.79)

178.5, <0.001

6.1%

8.2%

7.1%

1.15 (1.11, 1.18)

73.0, <0.001

7.1%

9.9%

8.5%

1.15 (1.12, 1.19)

103.0, <0.001

SSRI

SNRI
TCA

Other Antidepressants

Author Manuscript

Antipsychotics
Mood Stabilizers/Anti-Seizure

Wald X2, p-value

10.3%

14.0%

12.2%

1.21 (1.19, 1.24)

250.8, <0.001

Other Anxiolytics

0.9%

0.9%

0.9%

1.03 (0.94, 1.11)

0.34, 0.56

Miscellaneous Psychotropics

8.0%

8.0%

8.0%

0.93 (0.90, 0.96)

21.0, <0.001

1

Traumatic brain injury

2

Degrees of freedom=1

3

Selective serotonin reuptake inhibitors

4

Serotonin norepinephrine reuptake inhibitors

5

Tricyclic antidepressants

Author Manuscript
Author Manuscript
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Table 3

Author Manuscript

Among Patients Newly Diagnosed with Anxiety or Post-Traumatic Stress Disorder, Odds of Receiving
Indicated Pharmacologic Treatment Post-TBI Compared to Pre-TBI: Medicare Beneficiaries Hospitalized with
TBI 2006-2010
Odds Ratio (95% Confidence Interval)

Wald X2, p-value

0.52 (0.46, 0.58)

126.9, <0.001

0.42 (0.36, 0.48)

145.5, <0.001

0.32 (0.15, 0.67)

9.25, 0.002

0.39 (0.18, 0.84)

5.8, 0.02

Anxiety, n=5,078
Unadjusted

1

Adjusted

Post-traumatic Stress Disorder, n=85
Unadjusted

2

Adjusted

1

post-TBI, age, sex, race, calendar year, Alzheimer's disease and related dementias, depression pre-TBI, depression post-TBI

Author Manuscript

2

post-TBI, original reason for Medicare entitlement (age, disability, end-stage renal disease)
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